MX2020011844A - Anticuerpos bispecificos con marcadores con emparejamiento de cargas c-terminales escindibles. - Google Patents

Anticuerpos bispecificos con marcadores con emparejamiento de cargas c-terminales escindibles.

Info

Publication number
MX2020011844A
MX2020011844A MX2020011844A MX2020011844A MX2020011844A MX 2020011844 A MX2020011844 A MX 2020011844A MX 2020011844 A MX2020011844 A MX 2020011844A MX 2020011844 A MX2020011844 A MX 2020011844A MX 2020011844 A MX2020011844 A MX 2020011844A
Authority
MX
Mexico
Prior art keywords
cleavable
domain
bispecific antibodies
terminal charge
paired tags
Prior art date
Application number
MX2020011844A
Other languages
English (en)
Spanish (es)
Inventor
Kevin Graham
Stephen Smith
Dante ROMANINI
Christopher Mohr
Kawooya John K
Agrawal Neeraj J
Jacobitz Alex W
Ray Lieh Yoon Low
Oliver Thiel
Victoria Wagner
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2020011844A publication Critical patent/MX2020011844A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2020011844A 2018-05-08 2019-05-08 Anticuerpos bispecificos con marcadores con emparejamiento de cargas c-terminales escindibles. MX2020011844A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862668626P 2018-05-08 2018-05-08
PCT/US2019/031379 WO2019217587A1 (en) 2018-05-08 2019-05-08 Bispecific antibodies with cleavable c-terminal charge-paired tags

Publications (1)

Publication Number Publication Date
MX2020011844A true MX2020011844A (es) 2021-04-13

Family

ID=66676901

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020011844A MX2020011844A (es) 2018-05-08 2019-05-08 Anticuerpos bispecificos con marcadores con emparejamiento de cargas c-terminales escindibles.
MX2025001939A MX2025001939A (es) 2018-05-08 2020-11-05 Anticuerpos bispecificos con marcadores con emparejamiento de cargas c-terminales escindibles

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025001939A MX2025001939A (es) 2018-05-08 2020-11-05 Anticuerpos bispecificos con marcadores con emparejamiento de cargas c-terminales escindibles

Country Status (8)

Country Link
US (2) US12384849B2 (https=)
EP (1) EP3790904A1 (https=)
JP (3) JP2021523101A (https=)
AU (2) AU2019265699B2 (https=)
CA (1) CA3099450A1 (https=)
MA (1) MA52571A (https=)
MX (2) MX2020011844A (https=)
WO (1) WO2019217587A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020304671A1 (en) * 2019-06-28 2022-01-20 Amgen Inc. Anti-CGRP receptor/anti-PAC1 receptor bispecific antigen binding proteins
EP4466020A4 (en) * 2022-01-21 2026-04-15 Lyvgen Biopharma Holdings Ltd Multi-specific antibodies and their uses in avidity receptor cross-linking and immune modulation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US7101692B2 (en) * 1999-04-15 2006-09-05 The Regents Of The University Of California Identification of sortase gene
WO2001000814A2 (en) * 1999-06-25 2001-01-04 Universität Zürich Hetero-associating coiled-coil peptides and screenign method therefor
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US20050214300A1 (en) * 2002-11-25 2005-09-29 Chiron Corporation Methods for treating cancer using Porimin as a target
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
KR20120108967A (ko) 2009-09-16 2012-10-05 제넨테크, 인크. 코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도
EP2824111B1 (en) * 2010-04-30 2017-03-22 Alexion Pharmaceuticals, Inc. Anti-C5A Antibodies and Methods for Using the Antibodies
US10851178B2 (en) * 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
SG11201508732PA (en) * 2013-04-25 2015-11-27 Scripps Korea Antibody Inst Method for refining protein including self-cutting cassette and use thereof
RS61907B1 (sr) 2015-04-06 2021-06-30 Subdomain Llc Polipeptidi koji sadrže de novo vezujući domen i njihova primena
KR102095096B1 (ko) * 2015-08-26 2020-03-30 바이슨 테라퓨틱스 인크. 다중특이적 항체 플랫폼 및 관련 방법

Also Published As

Publication number Publication date
JP2024023264A (ja) 2024-02-21
AU2019265699A1 (en) 2021-01-07
US20220089756A1 (en) 2022-03-24
AU2019265699B2 (en) 2026-03-12
EP3790904A1 (en) 2021-03-17
JP7785734B2 (ja) 2025-12-15
AU2026201242A1 (en) 2026-04-23
JP2021523101A (ja) 2021-09-02
CA3099450A1 (en) 2019-11-14
MX2025001939A (es) 2025-04-02
US12384849B2 (en) 2025-08-12
MA52571A (fr) 2021-03-17
US20250197518A1 (en) 2025-06-19
WO2019217587A1 (en) 2019-11-14
JP2026035775A (ja) 2026-03-04

Similar Documents

Publication Publication Date Title
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
CO2018011668A2 (es) Neoantígenos y métodos de su uso
PE20221021A1 (es) Proteinas de union a antigeno que se unen especificamente a mage-a
MX2020001752A (es) Anticuerpos anti-cd3 y metodos de uso.
WO2018187356A3 (en) Protein antigens and uses thereof
WO2019086500A3 (en) Bispecific 2+1 contorsbodies
MX377605B (es) Inmunoglobulina híbrida conteniendo un enlace no-peptidílico.
MX2025012685A (es) Anticuerpos para claudin6 y metodos para tratar el cancer
PE20140218A1 (es) Composicion farmaceutica
AR091069A1 (es) Proteinas de union a antigeno dirigidas contra el receptor st2
MX377692B (es) Peptidos anti-inflamatorios y usos de los mismos.
AR077088A1 (es) Proteinas biespecificas de union a antigeno
EA201592006A1 (ru) Новые биспецифические связывающие молекулы с противоопухолевой активностью
MX361076B (es) Proteínas multifunción que comprenden complejo mayor de histocompatibilidad (cmh) de clase i multivalente unido mediante disulfuro.
EA202091054A1 (ru) Слитые молекулы на основе антитела против pd-l1 и ил-7
WO2019117685A3 (ko) 항-igf1r 항체 및 그 용도
PE20201149A1 (es) Anticuerpos de union a hla-a2/wt1
EA201691782A1 (ru) Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения
MX2021000155A (es) Moleculas de proteina multifuncionales que comprenden decorina y su uso.
MX2022000081A (es) Proteínas de unión al antígeno anti carcinoma de células escamosas esofágico 1 de nueva york (ny-eso-1) y métodos de uso.
EP4253959A3 (en) Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule
CL2018003072A1 (es) Anticuerpos anti-basigin humanizados y uso de los mismos.
PH12016500403A1 (en) An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof
WO2018071822A8 (en) ANTIBODIES BINDING TO THE ZIKA VIRUS ENVELOPE PROTEIN AND USES THEREOF
MX2025001939A (es) Anticuerpos bispecificos con marcadores con emparejamiento de cargas c-terminales escindibles